Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1–Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis

Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)–expressing esophageal squamous cell carcinoma (ESCC) by the European Medicines Agency, whereas the US Food and Drug Administration approved this regimen regardless of P...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Hao-Xiang, Pan, Yi-Qian, He, Ye, Wang, Zi-Xian, Guan, Wen-Long, Chen, Yan-Xing, Yao, Yi-Chen, Shao, Ning-Yi, Xu, Rui-Hua, Wang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022847/
https://www.ncbi.nlm.nih.gov/pubmed/36473145
http://dx.doi.org/10.1200/JCO.22.01490

Ejemplares similares

Ejemplares similares